These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 28024697

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.
    To KKW, Fu LW.
    Invest New Drugs; 2018 Feb; 36(1):10-19. PubMed ID: 28819699
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
    Liedert B, Materna V, Schadendorf D, Thomale J, Lage H.
    J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
    [Abstract] [Full Text] [Related]

  • 4. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    Materna V, Liedert B, Thomale J, Lage H.
    Int J Cancer; 2005 Jun 20; 115(3):393-402. PubMed ID: 15688364
    [Abstract] [Full Text] [Related]

  • 5. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L.
    Cancer Chemother Pharmacol; 2001 Nov 20; 48(5):398-406. PubMed ID: 11761458
    [Abstract] [Full Text] [Related]

  • 6. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
    Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.
    Biochem Pharmacol; 2015 Mar 15; 94(2):79-90. PubMed ID: 25600908
    [Abstract] [Full Text] [Related]

  • 7. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N, Werner J.
    BMC Cancer; 2012 Jun 08; 12():226. PubMed ID: 22681698
    [Abstract] [Full Text] [Related]

  • 8. Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.
    Kong LR, Tan TZ, Ong WR, Bi C, Huynh H, Lee SC, Chng WJ, Eichhorn PJA, Goh BC.
    Mol Oncol; 2017 Aug 08; 11(8):965-980. PubMed ID: 28397399
    [Abstract] [Full Text] [Related]

  • 9. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC, Peng RW, Dorn P, Froment L, Schmid RA, Marti TM.
    BMC Cancer; 2016 Feb 19; 16():125. PubMed ID: 26895954
    [Abstract] [Full Text] [Related]

  • 10. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
    Kim MJ, Lee JS, Park SE, Yi HJ, Jeong IG, Kang JS, Yun J, Lee JY, Ro S, Lee JS, Choi EK, Hwang JJ, Kim CS.
    J Urol; 2015 May 19; 193(5):1660-8. PubMed ID: 25433307
    [Abstract] [Full Text] [Related]

  • 11. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Xiao Y, Lin FT, Lin WC.
    Proc Natl Acad Sci U S A; 2021 Jan 19; 118(3):. PubMed ID: 33408251
    [Abstract] [Full Text] [Related]

  • 12. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 19; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 13. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 14. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Corte-Rodríguez M, Espina M, Sierra LM, Blanco E, Ames T, Montes-Bayón M, Sanz-Medel A.
    Biochem Pharmacol; 2015 Nov 01; 98(1):69-77. PubMed ID: 26352094
    [Abstract] [Full Text] [Related]

  • 15. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A.
    Mol Cancer; 2015 Jan 21; 14():4. PubMed ID: 25608569
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun 21; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 17. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.
    Cancer Chemother Pharmacol; 1997 Jun 21; 39(3):245-53. PubMed ID: 8996528
    [Abstract] [Full Text] [Related]

  • 18. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, Grant S.
    Blood; 2016 May 05; 127(18):2219-30. PubMed ID: 26851293
    [Abstract] [Full Text] [Related]

  • 19. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
    Chao CC.
    Eur J Pharmacol; 1996 Jun 03; 305(1-3):213-22. PubMed ID: 8813556
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
    Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L.
    Cell Cycle; 2011 Sep 15; 10(18):3119-28. PubMed ID: 21900747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.